Therapeutic progress. II: Treatment of psoriasis.
Treatment of psoriasis is rapidly changing with improved understanding of the pathogenesis of the disease. Newer topical preparations such as calcipotriol and immunosuppressive agents such as cyclosporin A and FK506 are having a major impact on the therapy of psoriasis. This article reviews the conventional therapies and newer agents used in the treatment of this common dermatosis.
Lewis
H M
HM
Department of Dermatology, General Hospital, Birmingham, U.K.
D000287:Administration, Topical; D000305:Adrenal Cortex Hormones / Q000008:administration & dosage / Q000627:therapeutic use; D000875:Anthralin / Q000008:administration & dosage / Q000627:therapeutic use; D002117:Calcitriol / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000627:therapeutic use; D003033:Coal Tar / Q000627:therapeutic use; D003131:Combined Modality Therapy; D016572:Cyclosporine / Q000008:administration & dosage / Q000627:therapeutic use; D003879:Dermatologic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D004643:Emollients / Q000627:therapeutic use; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D008727:Methotrexate / Q000009:adverse effects / Q000627:therapeutic use; D010789:Phototherapy; D011565:Psoriasis / Q000188:drug therapy* / Q000503:physiopathology / Q000628:therapy; D012176:Retinoids / Q000627:therapeutic use; D016559:Tacrolimus / Q000008:administration & dosage / Q000627:therapeutic use; D006113:United Kingdom
D000305:Adrenal Cortex Hormones; D003879:Dermatologic Agents; D004643:Emollients; D007166:Immunosuppressive Agents; D012176:Retinoids; C055085:calcipotriene; D003033:Coal Tar; D016572:Cyclosporine; D002117:Calcitriol; D000875:Anthralin; D016559:Tacrolimus; D008727:Methotrexate